Financials

  • Market Capitalization 9.35 B
  • Employee 1 402
  • Founded 1989
  • CEO Brett P. Monia Ph.D.
  • Website www.ionis.com
  • Headquarter California, United States
  • FIGI BBG000JH6683
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-33.24
Price to sales ratio
13.41

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
922
NUVL
Nuvalent, Inc. - Class A Common Stock
123.95 USD+0.04%+0.18%+0.48%+30.54%9.79 B USD
937
CORT
Corcept Therapeutics Incorporated - Common Stock
86.95 USD-5.37%-5.86%+4.87%+18.51%9.33 B USD
968
KYMR
Kymera Therapeutics, Inc. - Common Stock
110.24 USD-7.63%-4.83%+33.58%+86.53%9.07 B USD
971
HALO
Halozyme Therapeutics, Inc. - Common Stock
76.56 USD+0.47%-4.74%+7.82%+14.61%9.08 B USD

Frequently asked questions about Ionis Pharmaceuticals, Inc. - Common Stock

What is the Ionis Pharmaceuticals, Inc. - Common Stock stock price today?

The current price of Ionis Pharmaceuticals, Inc. - Common Stock (IONS) is 56.59. Over the past 24 hours, the stock has changed by -2.85%. Follow the IONS chart for real-time price dynamics.

What is the stock ticker of Ionis Pharmaceuticals, Inc. - Common Stock?

Ionis Pharmaceuticals, Inc. - Common Stock trades under the ticker IONS. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Ionis Pharmaceuticals, Inc. - Common Stock stock going up?

IONS has changed by -32.55% over the last week, -23.34% over the last month, and -21.54% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Ionis Pharmaceuticals, Inc. - Common Stock net income for the last quarter?

Ionis Pharmaceuticals, Inc. - Common Stock reported net income of -92.53 M for the last quarter. The previous quarter showed -229.39 M, which means net income changed by +59.66%.

How many employees does Ionis Pharmaceuticals, Inc. - Common Stock have?

As of the latest available data, Ionis Pharmaceuticals, Inc. - Common Stock has 1 402 employees. Workforce size can provide additional context about the company's scale and operations.

What is Ionis Pharmaceuticals, Inc. - Common Stock EBITDA?

Ionis Pharmaceuticals, Inc. - Common Stock EBITDA is -117.3 M, and its EBITDA margin is -47.67%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Ionis Pharmaceuticals, Inc. - Common Stock stock?

You can buy Ionis Pharmaceuticals, Inc. - Common Stock (IONS) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Ionis Pharmaceuticals, Inc. - Common Stock stock?

Investing in Ionis Pharmaceuticals, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the IONS chart and related analysis on metatrader.com as part of your research.

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.

News